Conversely, OGT or GFAT agonists could be combined with OGA inhibitors to increase O‐GlcNAcylation levels, offering new approaches for neurodegenerative diseases and some autoimmune disorders. The gene discussed is OGA; the disease is neurodegenerative disease.